The Business Strategy behind Clay B. Siegall Laudable Achievements

People excel by having access to secrets. These so-called secrets are not actually what they are called. It is the unrelenting adherence of individuals to them that make them one. Everybody may have access to them, but not everybody can hold-on to them in trying situations. Call them strategies, you will not be wrong. Clay B. Siegall has one strategy that has kept him going all these years. I got to know it when he was responding to questions in a recent interview. In his words, “Learn as much as you can; interact with very smart people who have expertise in many areas.” Narrowing this strategy to his profession, he put it this way: “An important component of our business strategy is collaborating with other industry leaders and innovators in oncology drug development.” He never sees himself or the company he runs as a island of knowledge, but can we find instances where he put this strategy into practice?

 

Clay B. Siegall holds a doctorate degree in Genetics from George Washington University. He is a Co-founder as well as the President, Chief Executive Officer and Board Chairman of Seattle Genetics since the inception of company in 1998. Being a specialist on targeted cancer therapies, Dr. Siegall entrenched into the fibers of the company a tradition of rigorous research, scientific innovation, drug development practices and unrelenting passion for assisting patients. Under his watch, the company has developed a number of effective antibody-drug conjugates (ADCs) with the FDA in 2011 approving the company’s first ADC product by the name ADCETRIS® (brentuximab vedotin). Thereafter, the company went into collaboration with Takeda Pharmaceutical Company making the drug a global brand available in over 65 countries.

 

Seattle Genetics has been involved in multiple strategic licenses for the purpose of financing its ADC technology. The company has had corporate agreements with companies such as Pfizer, GlaxoSmithKline, AbbVie and Genetics (Roche) generating well beyond $350 million. With the help of its numerous internal and collaborator programs, over 20 ADCs are in clinical development stages using Seattle Genetics’ technology.

 

Clay B. Siegall is one of the few indispensable hands combating the monster called cancer and providing hope of the eventual obliteration of the disease from planet earth.